Endothelial injury–related outcomes, engraftment, and GVHD outcomes
| . | No abatacept (n = 14) . | Abatacept (n = 50) . | P value . |
|---|---|---|---|
| Neutrophil engraftment, median (range), d | 11 (9-15) | 12 (9-14) | .1 |
| Platelet engraftment (20 × 103), median (range), d | 16 in 13 patients (12-81) | 18 (13-43) | .4 |
| Lowest myeloid chimerism anytime until last follow-up, % | 100 | 100 | 1.0 |
| Acute GVHD all grades, n (%) | 9 (64) | 7 (14) | .0004 |
| Acute visceral GVHD, n (%) | 5 (35) | 0 (0) | .0003 |
| Grade 2-4 GVHD, n (%) | 5 (35) | 0 (0) | .0003 |
| Grade 3-4 GVHD, n (%) | 5 (35) | 0 (0) | .0003 |
| Chronic GVHD, n (%) | 5 (35) | 7 (14) | .1 |
| Moderate-severe chronic GVHD, n (%) | 4 (28) | 5 (10) | .09 |
| Any endothelial injury–related event, n (%) | 9 (64) | 8 (16) | .0009 |
| TA-TMA all risk, n (%) | 9 (64) | 6 (12) | .002 |
| TA-TMA moderate and high risk, n (%) | 8 (57) | 3 (6) | <.001 |
| TA-TMA high risk, n (%) | 3 (21) | 2 (4) | .06 |
| SOS, n (%) | 2 (14) | 2 (4) | .2 |
| PRES, n (%) | 1 (7) | 1 (2) | .3 |
| DAH, n (%) | 0 (0) | 0 (0) | 1.0 |
| >1 endothelial injury event | 3 (TMA and SOS [n = 2]; TMA and PRES [n = 1]) | 1 (TMA and SOS) | .03 |
| . | No abatacept (n = 14) . | Abatacept (n = 50) . | P value . |
|---|---|---|---|
| Neutrophil engraftment, median (range), d | 11 (9-15) | 12 (9-14) | .1 |
| Platelet engraftment (20 × 103), median (range), d | 16 in 13 patients (12-81) | 18 (13-43) | .4 |
| Lowest myeloid chimerism anytime until last follow-up, % | 100 | 100 | 1.0 |
| Acute GVHD all grades, n (%) | 9 (64) | 7 (14) | .0004 |
| Acute visceral GVHD, n (%) | 5 (35) | 0 (0) | .0003 |
| Grade 2-4 GVHD, n (%) | 5 (35) | 0 (0) | .0003 |
| Grade 3-4 GVHD, n (%) | 5 (35) | 0 (0) | .0003 |
| Chronic GVHD, n (%) | 5 (35) | 7 (14) | .1 |
| Moderate-severe chronic GVHD, n (%) | 4 (28) | 5 (10) | .09 |
| Any endothelial injury–related event, n (%) | 9 (64) | 8 (16) | .0009 |
| TA-TMA all risk, n (%) | 9 (64) | 6 (12) | .002 |
| TA-TMA moderate and high risk, n (%) | 8 (57) | 3 (6) | <.001 |
| TA-TMA high risk, n (%) | 3 (21) | 2 (4) | .06 |
| SOS, n (%) | 2 (14) | 2 (4) | .2 |
| PRES, n (%) | 1 (7) | 1 (2) | .3 |
| DAH, n (%) | 0 (0) | 0 (0) | 1.0 |
| >1 endothelial injury event | 3 (TMA and SOS [n = 2]; TMA and PRES [n = 1]) | 1 (TMA and SOS) | .03 |